Literature DB >> 16234529

Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.

Marco Fiore1, Rosalba Miceli, Chiara Mussi, Salvatore Lo Vullo, Luigi Mariani, Laura Lozza, Paola Collini, Patrizia Olmi, Paolo G Casali, Alessandro Gronchi.   

Abstract

PURPOSE: Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade, cutaneous sarcoma with autocrine overproduction of the platelet-derived growth factor (PDGF) beta-chain from gene rearrangement as a key pathogenetic factor, now susceptible of molecular-targeted therapy. The aim of this retrospective analysis was to explore the outcome of patients with primary or recurrent DFSP. PATIENTS AND METHODS: Two hundred eighteen patients surgically treated at the Istituto Nazionale per lo studio e la cura dei Tumori (Milan, Italy) over 20 years were reviewed. Local relapse, distant metastasis, and survival were studied.
RESULTS: One hundred thirty-six patients (62.4%) presented with a primary DFSP, while 82 patients (37.6%) had a recurrent disease. In the primary group, margins were microscopically positive in 11.8%, while in the recurrent group they were positive in 14.6% (P =.613). In the primary group, patients undergoing re-excision after inadequate previous surgery had residual disease in 62% of cases. Reconstructive surgery was needed in 30%, significantly more frequently in patients with a recurrence or a head and neck tumor. The crude cumulative incidence of local relapses was 4% at 10 years, and 2% at 10 years for distant metastases. No significant difference was found between primary and recurrent patients, as well as between positive and negative margins.
CONCLUSION: This being one of the largest mono-institutional series of DFSP, we confirm that long-term outcome is excellent, in terms of both local and distant control, after a wide excision with negative margins. Reconstructive surgery is often needed. Novel medical therapies will be of use in a limited subgroup of patients.

Entities:  

Mesh:

Year:  2005        PMID: 16234529     DOI: 10.1200/JCO.2005.02.5122

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

Review 1.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  Dermatofibrosarcoma protuberans: a case report and review of the literature.

Authors:  D Paramythiotis; G Stavrou; D Panagiotou; G Petrakis; A Michalopoulos
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

3.  A Rare Breast Tumor: Dermatofibrosarcoma Protuberans.

Authors:  Tevhide Bilgen Özcan; Ezgi Hacıhasanoğlu; Mehmet Ali Nazlı; Şefika Aksoy; Cem Leblebici; Canan Kelten Talu
Journal:  J Breast Health       Date:  2016-01-01

4.  Clinicopathological features of dermatofibrosarcoma protuberans.

Authors:  Noppadol Larbcharoensub; Jitchai Kayankarnnavee; Suda Sanpaphant; Kidakorn Kiranantawat; Chewarat Wirojtananugoon; Vorachai Sirikulchayanonta
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

5.  Dermatofibrosarcoma protuberans: Our experience of 59 cases.

Authors:  Alessio Stivala; Giuseppe A G Lombardo; Gianluca Pompili; Maria Stella Tarico; Filippo Fraggetta; Rosario Emanuele Perrotta
Journal:  Oncol Lett       Date:  2012-08-30       Impact factor: 2.967

6.  Intracranial recurrence and distant metastasis of scalp dermatofibrosarcoma protuberans.

Authors:  Jurica Marakovic; Milorad Vilendecic; Tonko Marinovic; Smiljka Lambasa; Gordan Grahovac
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

7.  Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma.

Authors:  Jieun Lee; Young Je Park; Dae Sik Yang; Won Sup Yoon; Jung Ae Lee; Chai Hong Rim; Chul Yong Kim
Journal:  Radiat Oncol J       Date:  2012-06-30

Review 8.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

Review 9.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

10.  Imatinib in the treatment of dermatofibrosarcoma protuberans.

Authors:  Stefanos V Labropoulos; Evangelia D Razis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.